Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma

Int J Mol Sci. 2023 Apr 19;24(8):7506. doi: 10.3390/ijms24087506.

Abstract

Although gemcitabine (GEM) is widely used in chemotherapy for pancreatic ductal adenocarcinoma (PDA), drug resistance restricts its clinical effectiveness. To examine the mechanism of GEM resistance, we established two GEM-resistant cell lines from human PDA cells by continuous treatment with GEM and CoCl2-induced chemical hypoxia. One resistant cell line possessed reduced energy production and decreased mitochondrial reactive oxygen species levels, while the other resistant cell line possessed increased stemness. In both cell lines, ethidium bromide-stained mitochondrial DNA levels decreased, suggesting mitochondrial DNA damage. Inhibition of hypoxia-inducible factor-1α in both cell lines did not restore the GEM sensitivity. In contrast, treatment of both cell types with lauric acid (LAA), a medium-chain fatty acid, restored GEM sensitivity. These results suggest that decreased energy production, decreased mitochondrial reactive oxygen species levels, and increased stemness associated with mitochondrial damage caused by GEM lead to GEM resistance, and that hypoxia may promote this process. Furthermore, forced activation of oxidative phosphorylation by LAA could be a tool to overcome GEM resistance. Clinical verification of the effectiveness of LAA in GEM resistance is necessary in the future.

Keywords: drug resistance; gemcitabine; hypoxia; mitochondria; pancreatic cancer.

MeSH terms

  • Apoptosis
  • Carcinoma, Pancreatic Ductal* / pathology
  • Cell Line, Tumor
  • DNA, Mitochondrial / therapeutic use
  • Deoxycytidine / pharmacology
  • Deoxycytidine / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms* / metabolism
  • Reactive Oxygen Species

Substances

  • Gemcitabine
  • lauric acid
  • Deoxycytidine
  • Reactive Oxygen Species
  • DNA, Mitochondrial